Researchers at the University of Oxford, in collaboration with biopharmaceutical company NuCana, have developed a groundbreaking chemotherapy drug called NUC-7738, derived from the Himalayan fungus Cordyceps sinensis. Remarkably, this novel compound shows up to 40 times greater potency in killing cancer cells compared to its natural precursor, cordycepin (3′-deoxyadenosine).
From Ancient Medicine to Modern Breakthrough
Traditionally, healers have used cordycepin from Cordyceps sinensis in Chinese medicine to treat various ailments, including cancer. However, despite its potential, cordycepin has faced serious limitations because it rapidly degrades in the bloodstream and struggles with cellular uptake.
To solve these issues, Oxford researchers employed an advanced method known as ProTide technology. Previously successful in antiviral drugs like Remdesivir and Sofosbuvir, this technology now boosts the stability and delivery of cordycepin. As a result, NUC-7738 can bypass resistance mechanisms and attack cancer cells more effectively.
Early Trials Offer Hope
Importantly, early-phase clinical trials of NUC-7738 have already delivered encouraging results. Patients tolerated the drug well, and it demonstrated significant anti-cancer activity. Therefore, experts believe that NUC-7738 could soon provide a more effective and safer alternative to conventional chemotherapy.
A New Frontier in Cancer Therapy
Ultimately, the development of NUC-7738 shows how blending traditional medicinal knowledge with modern pharmaceutical innovation can lead to powerful, next-generation cancer treatments. With further research and clinical success, this fungus-derived drug could reshape the future of oncology.
